Pipeline and R&D programs

In 2015, Ipsen’s R&D expenditure totaled close to €193 million, representing more than 13% of Group sales.

Ipsen’s R&D activities are focused on the discovery and development of new molecules and on programs for the lifecycle management of products already marketed by the group (new formulations, extension of indications and registration of products in new geographical areas).

 Phase IPhase IPhase IIPhase III
Oncology

NOVEL RADIOPHARMACEUTICALS

(Licensed from 3B Pharma)
In progress in 2015

PEPTIDE RECEPTOR RADIONUCLIDE THERAPY

177LU-OPS201
In progress in 2015

TRANSMEMBRANE ONCOLOGY TARGET

In progress in 2015

INTRACELLULAR ONCOLOGY TARGET

In progress in 2015

68GA-ops202

Diagnostic agent for NET
Completed in 2015/Early 2016

CABOZANTINIB

Renal cell carcinoma (First line) (Partnership with Exelixis)
In progress in 2015

TELOTRISTAT ETIPRATE

Carcinoid syndrome (Partnership with Lexicon)
Completed in 2015/Early 2016

CABOZANTINIB

Renal cell carcinoma (Second line) (Partnership with Exelixis)
Completed in 2015/Early 2016

CABOZANTINIB

Hepatocellular carcinoma (Second line) (Partnership with Exelixis)
In progress in 2015
Neurosciences

NOVEL BOTULINUM TOXIN

In progress in 2015

LRRK2

(Partnership with Oncodesign)
In progress in 2015

VSN 16R

Spasticity in multiple sclerosis (Study performed by Canbex under an option to acquire)
In progress in 2015

BN82451B

Huntington disease
In progress in 2015

DYSPORT®

Adult lower limb spasticity
In progress in 2015

DYSPORT® 

Pediatric upper limb spasticity
In progress in 2015

DYSPORT® NEXT GENERATION

Glabellar lines
In progress in 2015

DYSPORT®

Glabellar lines
In progress in 2015

DYSPORT®

Pediatric lower limb spasticity
Completed in 2015/Early 2016
Endocrinology

G PROTEIN-COUPLED RECEPTORS

In progress in 2015

BIM23B065

Cushing disease
Completed in 2015/Early 2016

SOMATULINE® PROLONGED RELEASE FORMULATION

Acromegaly
In progress in 2015
Updated on 31 March 2016